Cancer Clinical Trial
Official title:
Feasibility and Effectiveness of an Innovative Exercise Program to Reduce Fatigue in Rural Cancer Survivors
Verified date | June 2024 |
Source | University of Colorado, Denver |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objective of this investigation is to establish the feasibility and initial effectiveness of a novel exercise program for rural cancer survivors in Colorado suffering from cancer related fatigue. Participation in an exercise program has regularly been shown to reduce fatigue in cancer survivors, though in-person, supervised participation has a greater effect on fatigue than home-based programs with no supervision. Access to these supervised programs are limited in rural areas, restricting the ability of rural cancer survivors to experience the fatigue-reducing benefits of exercise. The proposed program will use information on improvements in fatigue from participants in the BfitBwell Cancer Exercise Program to monitor improvements in fatigue in rural cancer survivors performing a home exercise program and trigger a telehealth session with a cancer exercise specialist to adapt the exercise prescription when improvements are less than expected. The BfitBwell Program is an established exercise program at the Anschutz Health and Wellness Center which has worked with over 600 cancer survivors and is highly effective at reducing cancer related fatigue. The goal of the program is to replicate the effects of a successful supervised exercise program in rural cancer survivors who do not have access to this type of program. This investigation will recruit 20 rural cancer survivors experiencing fatigue and assess their ability to participate in the program, as well as how well the program improves their fatigue. Interviews will be conducted with participants after the program to determine how future versions of the program could be improved. The investigators anticipate that this program will be feasible and effective, providing preliminary data to pursue a large-scale clinical trial of the program following this project's completion.
Status | Active, not recruiting |
Enrollment | 19 |
Est. completion date | May 2025 |
Est. primary completion date | April 12, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Adult (>= 18 years) cancer survivor treated at the University of Colorado Cancer Center o A maximum age of 80 will be set as virtual exercise may become unsafe as individuals get older. - A primary cancer diagnosis of breast, prostate, or lung cancer - Current report of moderate-to-severe fatigue (> 3 on a 0-10 scale, per NCCN definition30) - Live in rural Colorado (> 1-hour commute to major front range city [Denver, Fort Collins, and Colorado Springs]) - Completed medical cancer treatment (chemotherapy and/or radiation) with curative intent within past 12 months. o No additional treatment planned for next 4 months - High-speed home internet and smartphone Exclusion Criteria: - Medical conditions that would impact the safety of, or participation in, an exercise program. This includes: - Orthopedic conditions such as advanced osteoarthritis, mobility-limiting amputations or chronic injuries, or mobility-limiting acute orthopedic injuries - Advanced rheumatoid arthritis - Widespread chronic pain conditions such as fibromyalgia - Pulmonary conditions such as chronic obstructive pulmonary disease, emphysema, interstitial lung disease, use of supplemental oxygen - Known cardiovascular disease, uncontrolled hypertension, or new cardiac event within the past 6 months. |
Country | Name | City | State |
---|---|---|---|
United States | Anschutz Health and Wellness | Aurora | Colorado |
Lead Sponsor | Collaborator |
---|---|
University of Colorado, Denver | Cancer League of Colorado |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Ecological momentary assessments of fatigue | 11 point fatigue intensity scale with higher scores indicating increased fatigue | Semi-continuous throughout program, up to 12 weeks | |
Other | The Feeling Scale - Pre-exercise | 11 point scale of perceived affect during exercise, positive scores indicating positive affect, negative scores indicating negative affect | Immediately before each exercise session | |
Other | The Feeling Scale - Post-exercise | 11 point scale of perceived affect during exercise, positive scores indicating positive affect, negative scores indicating negative affect | Immediately after each exercise session | |
Other | Rate of perceived exertion | 11 point scale of perceived work/intensity during exercise. Higher scores indicate more intense workout. | Immediately after every exercise session | |
Primary | Change in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) at 12 weeks | 13-item instrument widely used to assess cancer related fatigue. Score range: 0-52. Lower scores indicate more fatigue. | Baseline (week 0), 12 weeks | |
Secondary | Changes in Steps per day | Average steps per day over a 7 day period, assessed with commercial fitness tracker | Baseline (week 0), 12 weeks | |
Secondary | Changes in Average sleep time | Average sleep time per day over a 7 day period, assessed with commercial fitness tracker | Baseline (week 0), 12 weeks | |
Secondary | Changes in Single limb stance | Time participant can stand on one leg, up to 30 s | Baseline (week 0), 12 weeks | |
Secondary | Changes in Gait speed | Gait speed over a 4 m distance, in m/s | Baseline (week 0), 12 weeks | |
Secondary | Changes in Timed up and go | Time (in s) to rise from a chair, walk 3 m, turn around, walk back to chair, and sit down | Baseline (week 0), 12 weeks | |
Secondary | Changes in 30 s Sit-to-Stand | Number of times one can stand and sit from a chair in 30 s | Baseline (week 0), 12 weeks | |
Secondary | Changes Tecumseh Step Test | Participants steps on and off an 8" step at a rate of 24 steps/min for 3 min. Heart rate is recorded at 30 s and 1 min after completion. | Baseline (week 0), 12 weeks | |
Secondary | Changes in Functional Assessment of Cancer Therapy-General form (FACT-G) at 12 weeks | Common questionnaire assessing health related quality of life in cancer survivors, range 0-108, higher scores indicate better quality of life | Baseline (week 0), 12 weeks | |
Secondary | Changes in Functional Assessment of Cancer Therapy-General form (FACT-G) at 6 month | Common questionnaire assessing health related quality of life in cancer survivors, range 0-108, higher scores indicate better quality of life | Baseline (week 0), 6 months | |
Secondary | Changes in Functional Assessment of Cancer Therapy-General form (FACT-G) at 9 months | Common questionnaire assessing health related quality of life in cancer survivors, range 0-108, higher scores indicate better quality of life | Baseline (week 0), 9 months | |
Secondary | Changes in Functional Assessment of Cancer Therapy-General form (FACT-G) at 15 months | Common questionnaire assessing health related quality of life in cancer survivors, range 0-108, higher scores indicate better quality of life | Baseline (week 0), 15 months | |
Secondary | Changes in Multidimensional Fatigue Inventory (MFI) at 12 weeks | Questionnaire with multiple subscales of fatigue identified. Score range: 0-100, higher scores indicate increased fatigue | Baseline (week 0), 12 weeks | |
Secondary | Changes in Multidimensional Fatigue Inventory (MFI) at 6 months | Questionnaire with multiple subscales of fatigue identified. Score range: 0-100, higher scores indicate increased fatigue | Baseline (week 0), 6 months | |
Secondary | Changes in Multidimensional Fatigue Inventory (MFI) at 9 months | Questionnaire with multiple subscales of fatigue identified. Score range: 0-100, higher scores indicate increased fatigue | Baseline (week 0), 9 months | |
Secondary | Changes in Multidimensional Fatigue Inventory (MFI) at 15 months | Questionnaire with multiple subscales of fatigue identified. Score range: 0-100, higher scores indicate increased fatigue | Baseline (week 0), 15 months | |
Secondary | Changes in Hospital Anxiety and Depression Scale (HADS) at 12 weeks | Questionnaire to assess anxiety and depression in populations with medical conditions. Score range: 0-42, higher scores indicate presence of anxiety and depression | Baseline (week 0), 12 weeks | |
Secondary | Changes in Hospital Anxiety and Depression Scale (HADS) at 6 months | Questionnaire to assess anxiety and depression in populations with medical conditions. Score range: 0-42, higher scores indicate presence of anxiety and depression | Baseline (week 0), 6 months | |
Secondary | Changes in Hospital Anxiety and Depression Scale (HADS) at 9 months | Questionnaire to assess anxiety and depression in populations with medical conditions. Score range: 0-42, higher scores indicate presence of anxiety and depression | Baseline (week 0), 9 months | |
Secondary | Changes in Hospital Anxiety and Depression Scale (HADS) at 15 months | Questionnaire to assess anxiety and depression in populations with medical conditions. Score range: 0-42, higher scores indicate presence of anxiety and depression | Baseline (week 0), 15 months | |
Secondary | Change in Godin Leisure-Time Physical Activity Questionnaire (GLTPAQ) at 12 weeks | Self-report of time spent in light, moderate, and vigorous physical activity in minutes. | Baseline (week 0), 12 weeks | |
Secondary | Change in Godin Leisure-Time Physical Activity Questionnaire (GLTPAQ) at 6 months | Self-report of time spent in light, moderate, and vigorous physical activity in minutes. | Baseline (week 0), 6 months | |
Secondary | Change in Godin Leisure-Time Physical Activity Questionnaire (GLTPAQ) at 9 months | Self-report of time spent in light, moderate, and vigorous physical activity in minutes. | Baseline (week 0), 9 months | |
Secondary | Change in Godin Leisure-Time Physical Activity Questionnaire (GLTPAQ) at 15 months | Self-report of time spent in light, moderate, and vigorous physical activity in minutes. | Baseline (week 0), 15 months | |
Secondary | Change in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) at 6 months | 13-item instrument widely used to assess cancer related fatigue. Score range: 0-52. Lower scores indicate more fatigue. | Baseline (week 0), 6 months | |
Secondary | Change in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) at 9 months | 13-item instrument widely used to assess cancer related fatigue. Score range: 0-52. Lower scores indicate more fatigue. | Baseline (week 0), 9 months | |
Secondary | Change in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) at 15 months | 13-item instrument widely used to assess cancer related fatigue. Score range: 0-52. Lower scores indicate more fatigue. | Baseline (week 0), 15 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|